EW

Edwards Lifesciences Corporation

Fundamental data last updated:June 7, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NYSE

County of HQ

US

Next Earnings Date

07/23/2026

Business Summary

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

 


VALUATION

P/E

45.56

Market Cap ($M USD)

$49.50B

Forward P/E

18.73

PEG

0.13

PRICE TO SALES

7.85

PRICE TO BOOK

4.82

EV / EBITDA

33.26

5-Year Average P/E

Free Cash Flow Yield

2.20%

DCF Value

$61.83

Graham Number

$27.51

Price to FCF

45.43

EV to FCF

43.83

Earnings Yield

2.19%

FCF Yield

2.20%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.89

Next Year EPS Growth Estimate

$4.59

Next Year Revenue Growth Estimate

$978.93B

Return on Equity (ROE)

10.55%

FREE CASH FLOW

Operating Margin

27.62%

Debt-to-Equity

0.07

Piotroski F-Score

6

Altman Z-Score

12.86

Return on Invested Capital (ROIC)

14.62%

Current Ratio

4.42

Quick Ratio

3.63

Net Debt to EBITDA

-1.21

Interest Coverage

0.00

Gross Profit margin

78.01%

FCF PER SHARE

$1.88

REVENUE PER SHARE

$10.88

Gainseekers Quantitative Analysis

Summary

Edwards Lifesciences Corporation’s valuation paints a complex picture. While the market cap is substantial, the stock traded above its DCF value, suggesting potential overvaluation. The Forward P/E of 17.42 is more reasonable, indicating expectations for future growth. The Altman Z-score of 11.99 signals robust financial health, mitigating bankruptcy risk. However, the earnings yield of 2.36% is lackluster, raising questions about immediate returns.

AI Exposure / Tech Reliance

Operating in the medical devices industry, Edwards Lifesciences is well-positioned to leverage AI advancements in healthcare. Their focus on innovative heart valve technologies aligns with the increasing integration of AI in medical diagnostics and treatment. This adaptability could enhance their competitive edge in a rapidly evolving tech landscape.

The Bull Case

For the discerning GARP investor, Edwards Lifesciences offers compelling strengths. A ROIC of 14.62% reflects efficient capital allocation, while a Piotroski F-Score of 6 indicates solid financial health. The impressive operating margin of 27.62% underscores strong pricing power. Despite a modest FCF yield, the company's ability to generate cash flow remains a positive indicator of long-term value.

The Bear Case

Yet, the stock is not without its flaws. The Price/Sales ratio of 7.30 and Price/Book of 4.48 suggest a premium valuation, potentially limiting upside. With the stock trading close to its 52-week high, technical overextension is a concern. Additionally, the EV to EBITDA ratio of 30.82 highlights a rich valuation, which could deter value-focused investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$96.83

Institutional Ownership %

1-Year Beta

0.87

Insider Buying % (6 Mo)

Distance to 52-Week High

4.05%

Distance to 52-Week Low

15.89%

EARNINGS SURPRISE %

7.00%

50-DAY SMA

$82.04

200-DAY SMA

$81.64

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.